Evidence map›Paper›PMID 37118760›Full record

ArticleExperimental hematology & oncology2023

New approaches to idiopathic neutropenia in the era of clonal hematopoiesis.

Olisaemeka D Ogbue, Tariq Kewan, Waled S Bahaj, Carmelo Gurnari, Valeria Visconte, Jaroslaw P Maciejewski

Open access · goldAbstract readLetter
In one paragraph

Article in Experimental hematology & oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Observational
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Olisaemeka D Ogbue *Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, 9620 Carnegie Ave N Building, Building NE6-250, Cleveland, OH, 44106, USA.
Tariq Kewan *Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, 9620 Carnegie Ave N Building, Building NE6-250, Cleveland, OH, 44106, USA.
Waled S BahajDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, 9620 Carnegie Ave N Building, Building NE6-250, Cleveland, OH, 44106, USA.
Carmelo GurnariDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, 9620 Carnegie Ave N Building, Building NE6-250, Cleveland, OH, 44106, USA.
Valeria VisconteDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, 9620 Carnegie Ave N Building, Building NE6-250, Cleveland, OH, 44106, USA.
Jaroslaw P MaciejewskiDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, 9620 Carnegie Ave N Building, Building NE6-250, Cleveland, OH, 44106, USA. maciejj@ccf.org.
Translational Research in Oncology · FRUniversity of Louisville · USUniversity of Rome Tor Vergata · ITYale University · US

Funding

Therapeutic Implications of Molecular Defects in Bone Marrow FailureR35HL135795 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI MACIEJEWSKI, JAROSLAW P. · 2017 to 2023
$5.7M
NHLBI NIH HHS R35 HL135795
6 · The paper itself

Abstract

Isolated chronic idiopathic neutropenia (CIN) is a rare disease with multiple contributing etiologies that must be ruled out before establishing a diagnosis. We studied clinical and molecular data of 238 consecutive adult patients with CIN. Autoimmune neutropenia was present in 28% of our cohort. In contrast, T cell-mediated neutropenia was the main underlying pathological mechanism among patients with T cell expansions, such as T-cell large granular lymphocytic leukemia (T-LGL) and T cell clonopathy of undetermined significance, found in 37% and 8% of cases, respectively. Patients with neutropenia also had hypogammaglobulinemia (6%) and/or monoclonal gammopathy of undetermined significance (5%). NGS application has further broadened the spectrum of causes of CIN by including manifestations of clonal hematopoiesis, present in 12% of cases. TET2 (3%), TP53 (2%), and IDH1/IDH2 (2%) mutations were the most commonly found and were enriched in cases with T-LGL. We show that these clinico-molecular associations can be simultaneously present, complicating a proper diagnostic distinction within the broader entity of seemingly idiopathic neutropenia of autoimmune origin. Identification of etiologic culprits may also guide rational selection of therapies.

Indexed as

Clonal hematopoiesisNeutropeniaT-cell mediated

Identifiers

PMID37118760
PMCPMC10148514
OpenAlexW4367312596

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.